iRhythm Holdings Inc. (IRTC)
NASDAQ: IRTC · Surgical & Medical Instruments & Apparatus · San Francisco, CA
Our rating: Positive
Call changed from Neutral to Positive at $93.56, moderate conviction, November 12, 2026.
Breaks if: The Positive view breaks if revenue growth decelerates below 15% on a trailing-twelve-month basis at any of the next three quarterly prints, or if free cash flow turns negative for two consecutive quarters — either outcome would indicate the franchise is losing volume or pricing momentum faster than the current trajectory implies and would remove the core justification for holding a premium multiple on a still-loss-making business.
Key figures
| Market value | $3.2B |
|---|---|
| Revenue, last 12 months | $854M |
| Net income, last 12 months | −$39M |
| Free cash flow, last 12 months | $7M |
| Price to earnings | n/a |
| Free cash flow yield | 0.2% |
| Dividend yield | 0.0% |
| Operating margin | −5.7% |
| Return on equity | −25.8% |
| Beta to the S&P 500 | 0.76 |
| Volatility, annualized | 53.2% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $222M | 14.9% | $-0.90 | −$12M |
| June 30, 2026 | $224M | 20.1% | $-0.01 | $38M |
| March 31, 2026 | $199M | 25.7% | $-0.43 | −$33M |
| December 31, 2025 | $209M | 27.1% | $0.18 | $14M |
| September 30, 2025 | $193M | 30.7% | $-0.16 | $20M |
| June 30, 2025 | $187M | 26.1% | $-0.44 | $17M |
| March 31, 2025 | $159M | 20.3% | $-0.97 | −$17M |
| December 31, 2024 | $164M | 24.0% | $-0.04 | $12M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.25B: Claude 52%, Gemini 35%, Mistral 45%
- Diluted earnings per share are at least $0.18: Claude 22%, Gemini 10%, Mistral 20%
- Free cash flow for the quarter is at least $0.01B: Claude 55%, Gemini 75%, Mistral 55%
15 ledger entries and 56 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.